What is a veterinary biomarker?

A biomarker is a measurable substance in blood whose concentration reflects a specific organ or process. Examples include SDMA and cystatin C for kidney function, NT-proBNP for cardiac stress, pancreatic lipase for pancreatitis, CRP/SAA for inflammation, and thyroid hormones for endocrine status.

Why is quantitative biomarker testing better than qualitative?

Quantitative results give a number with units, not just positive/negative. That number can be compared against a reference range, tracked over time as a trend, and used to stage disease (such as IRIS CKD staging by SDMA). Trends reveal whether a patient is improving or deteriorating before clinical signs change.

Which biomarkers should I monitor in a senior pet?

For senior dogs and cats, the core panel is SDMA (kidney), NT-proBNP (heart), and T4/TSH (thyroid), plus CRP or SAA if inflammation is suspected. These detect the most common age-related diseases — chronic kidney disease, heart disease, and hyperthyroidism — often before signs appear.

How often should biomarkers be monitored?

Kidney and cardiac biomarkers are typically checked every 3–6 months in chronic disease, inflammation markers during and after treatment, and thyroid hormones 4–6 weeks after starting medication. Serial trends matter more than any single value.

What is the difference between SDMA and creatinine?

SDMA rises when only about 25–40% of kidney function is lost, whereas creatinine does not increase until roughly 60–75% is gone. SDMA is also independent of muscle mass, so it stays accurate in cachectic or geriatric patients where creatinine is unreliable.

Can a single blood sample screen multiple organs?

Yes. One serum or plasma sample can be split across several quantitative assays on an immunofluorescence analyzer — SDMA for kidney, NT-proBNP for heart, T4/TSH for thyroid, and CRP/SAA for inflammation — giving a multi-organ snapshot from one draw.

Does hemolysis affect biomarker results?

Hemolysis can interfere with fluorescence-based immunoassays and alter some biomarker values, so visibly hemolyzed samples should be recollected when possible. Lipemia and icterus can also interfere, which is why proper sample handling is part of accurate quantitative testing.

Can I run these biomarker tests on the Migibio FIA680 or FIA880?

Yes. The Migibio FIA680 and FIA880 immunofluorescence analyzers run quantitative biomarker panels including SDMA, cystatin C, NT-proBNP, cPL/fPL, CRP/SAA, cortisol, and thyroid hormones, returning numeric results in about 10–20 minutes from serum or plasma.

SDMA and NT-proBNP: Kidney and Heart Markers in Pets

TL;DR — Biomarkers are blood molecules that flag what’s happening inside a specific organ before a pet looks sick. SDMA and cystatin C reveal kidney decline at ~25–40% function loss; NT-proBNP flags cardiac stress; cPL/fPL diagnose pancreatitis; CRP/SAA grade inflammation; cortisol and thyroid hormones map the endocrine system. Quantitative immunofluorescence testing turns these into numbers you can trend over time — the difference between catching early disease and waiting for symptoms.

In Plain Terms

Think of your diagnostics like a car dashboard. Routine chemistry — creatinine, BUN, ALT — is the odometer: it only moves after a lot of distance. Biomarkers like SDMA and NT-proBNP are the warning lights — the oil-pressure lamp, the tire-pressure sensor. They flick on the moment something starts to go wrong, long before the engine stalls. A normal chemistry panel is a car with no warning lights on. A biomarker panel tells you which light is about to come on — and gives you time to pull over.

Why Biomarkers Matter

Here’s the uncomfortable truth about veterinary medicine: pets hide illness. A dog or cat with 60% of its kidney function gone can look completely normal at home. By the time a client notices they’re drinking more, losing weight, or just “slowing down,” the disease has often been running for months.

Blood chemistry panels — creatinine, BUN, ALT — catch a lot. But they’re late signals for many organs. Creatinine only moves once roughly 60–75% of nephron function is already lost. A normal chemistry panel, in other words, is not the same as a healthy patient.

That’s where biomarkers come in.

What is a biomarker? A biomarker is a measurable substance in blood, plasma, or serum whose concentration reflects a specific organ or biological process. In small-animal practice, the workhorse biomarkers are SDMA and cystatin C (kidney), NT-proBNP (heart), cPL and fPL (pancreas), CRP and SAA (inflammation), and cortisol plus T4/TSH (endocrine). Each is more sensitive than traditional chemistry for its organ — meaning it rises earlier.

This guide walks through each group: what it measures, the reference ranges you should know, when to reach for it, and how quantitative immunofluorescence testing makes the whole thing faster and more precise.

The Biomarker Landscape at a Glance

Organ / System	Biomarker	Species	Normal Range	Flags Disease When
Kidney	SDMA	Dog & Cat	0–14 µg/dL	>14 (persistent), >18 = CKD
Kidney	Cystatin C	Dog / Cat	0.5–1.2 / 0.6–1.8 mg/L	Above reference (assay-dependent)
Heart	NT-proBNP	Dog	<900 pmol/L	>900 (grey zone 900–1800)
Heart	NT-proBNP	Cat	<100 pmol/L	>270 (grey zone 100–270)
Pancreas	cPL	Dog	<200 µg/L	>400 (equivocal 200–400)
Pancreas	fPL	Cat	≤3.5 µg/L	≥5.4 (equivocal 3.6–5.3)
Inflammation	CRP	Dog	<10 mg/L	>35 (low-grade 10–35)
Inflammation	SAA	Cat	<10 µg/mL	>10 (severe >100)
Endocrine	Cortisol	Dog	2–6 µg/dL basal	>22 post-ACTH (Cushing’s)
Endocrine	Total T4	Dog / Cat	1.0–4.0 / 0.8–4.0 µg/dL	<1.0 (hypo) / >4.0 (hyper)
Endocrine	TSH	Dog	<0.6 ng/mL	Elevated + low T4 = hypothyroid

Reference intervals are laboratory- and assay-dependent. Always use your analyzer’s validated range — the table is a clinical starting point, not a substitute.

Renal Biomarkers: Catching Kidney Disease Before Creatinine Moves

Chronic kidney disease (CKD) is one of the most common diagnoses in aging cats and dogs — and one of the most preventable in terms of progression, if it’s caught early. The problem has always been detection.

The Problem with Creatinine

Creatinine is the traditional renal marker, and it has two well-known weaknesses:

It’s late. Creatinine rises only after roughly 60–75% of nephron function is lost. A pet can have significant, progressive kidney damage and a perfectly normal creatinine.
It’s muscle-mass dependent. In a cachectic geriatric cat or a wasted senior dog, creatinine runs artificially low — masking real kidney disease.

This is why so many CKD cases present at Stage 3 or 4, when options are limited.

Why SDMA Is Different

Symmetric dimethylarginine (SDMA) is a methylated amino acid released at a constant rate by nucleated cells and cleared almost entirely by glomerular filtration. Two properties make it a game-changer:

It rises early. SDMA increases when only ~25–40% of kidney function is lost — well before creatinine moves.
It’s independent of muscle mass. SDMA doesn’t care how thin the patient is.

A persistent SDMA >14 µg/dL is abnormal. When creatinine is still within reference range, an elevated SDMA supports Stage 1 CKD — early, subclinical kidney disease that can be managed with diet and monitoring rather than waiting for azotemia.

Cystatin C: The Other Early Marker

Cystatin C is a low-molecular-weight protein produced by all nucleated cells and freely filtered by the glomerulus. Like SDMA, it’s muscle-mass-independent and rises earlier than creatinine. Reference ranges are roughly 0.5–1.2 mg/L in dogs and 0.6–1.8 mg/L in cats, though these are assay-dependent — a meaningful caveat, since there’s no single universal interval.

In practice, SDMA and cystatin C are complementary. SDMA has the stronger published evidence base and is the standard for IRIS staging; cystatin C is a useful independent confirmatory marker. For a full comparison, see SDMA vs. Cystatin C: Which Kidney Marker to Choose.

IRIS Staging: Turning a Number into a Plan

The International Renal Interest Society (IRIS) staging system is the global standard for CKD. It uses creatinine and SDMA to assign a stage:

IRIS Stage	Dog Creatinine (mg/dL)	Cat Creatinine (mg/dL)	SDMA (µg/dL)	Interpretation
Stage 1	<1.4	<1.6	<18	Non-azotemic; other abnormality present
Stage 2	1.4–2.8	1.6–2.8	18–35	Mild renal azotemia
Stage 3	2.9–5.0	2.9–5.0	36–54	Moderate renal azotemia
Stage 4	>5.0	>5.0	>54	Severe renal azotemia

A persistent SDMA above 14 µg/dL with a normal creatinine lands a patient in Stage 1 — the window where intervention has the biggest impact.

Related products: SDMA CKD Kit · Canine Cystatin C Test · Feline Cystatin C Test

Cardiac Biomarkers: NT-proBNP and the Stressed Heart

Heart disease in dogs and cats is often silent until it isn’t. The clinical sign that finally forces a diagnosis — labored breathing, collapse, a distended abdomen — is frequently the sign that means decompensation has already started.

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is released when cardiac muscle stretches under pressure or volume overload. It’s the closest thing small-animal medicine has to a “cardiac troponin” for congestive failure:

Dogs: <900 pmol/L is normal. 900–1800 pmol/L is a grey zone warranting follow-up; >1800 pmol/L is strongly suggestive of significant heart disease or CHF.
Cats: <100 pmol/L is normal. 100–270 pmol/L is a grey zone; >270 pmol/L supports cardiac disease.

The single most valuable use of NT-proBNP in practice is triaging the dyspneic patient. When a cat presents breathing hard, NT-proBNP helps answer the question that changes everything: is this heart failure or primary respiratory disease? In a coughing older dog, it helps distinguish cardiac cough from airway disease.

The full clinical picture is in NT-proBNP Testing in Dogs and Cats: Detecting Heart Disease Early.

Related products: Canine NT-proBNP Test · Feline NT-proBNP Test

Pancreatic Biomarkers: cPL and fPL

Pancreatitis is chronically under-diagnosed in both species — and historically hard to confirm. Amylase and lipase, the old standbys, are neither sensitive nor specific. The modern answer is pancreatic lipase immunoreactivity, which is species-specific:

Canine cPL: <200 µg/L normal; 200–400 µg/L equivocal; >400 µg/L consistent with pancreatitis.
Feline fPL: ≤3.5 µg/L normal; 3.6–5.3 µg/L equivocal; ≥5.4 µg/L consistent with pancreatitis.

The magnitude roughly tracks severity, and — importantly — cPL and fPL are not interchangeable. You can’t run a dog assay on a cat sample and expect a valid number.

For everything from sample handling to interpreting grey-zone results, see Canine cPL and Feline fPL: Diagnosing Pancreatitis with Confidence.

Related products: Canine Pancreatic Lipase Test · Feline Pancreatic Lipase Test

Inflammatory Biomarkers: CRP and SAA

When a patient “just isn’t right” — fever of unknown origin, post-op complications, a chronic condition that flares — inflammation is usually the common thread. Acute-phase proteins measure it directly:

Canine CRP: <10 mg/L normal; 10–35 mg/L low-grade; >35 mg/L active systemic inflammation.
Feline SAA: <10 µg/mL normal; >10 µg/mL active inflammation, with >100 µg/mL indicating severe disease.

Here’s the clinical insight that makes these markers genuinely useful: they’re fast in, fast out. CRP and SAA rise within hours of an inflammatory insult and fall just as quickly when treatment works. That makes them ideal for serial monitoring — a falling CRP tells you the antibiotic is working days before the patient looks better, and a rising SAA flags a complication before it’s obvious.

Neither marker identifies the cause of inflammation. They tell you how much inflammation is present and whether it’s responding. That’s a different, and often more actionable, question. Details in CRP and SAA: Grading Inflammation in Dogs and Cats.

Related products: Canine CRP Test · Feline SAA Test

Endocrine Biomarkers: Thyroid and Cortisol

Endocrine disease is the great masquerader. Hyperthyroid cats lose weight while eating ravenously; hypothyroid dogs gain weight while barely eating; Cushingoid dogs drink and urinate relentlessly. The clinical signs overlap with half the differential list — which is why the numbers matter.

Thyroid: T4 and TSH

Canine hypothyroidism: total T4 <1.0 µg/dL (reference ~1.0–4.0), ideally with an elevated TSH — the classic primary hypothyroidism pattern.
Feline hyperthyroidism: total T4 >4.0 µg/dL (reference ~0.8–4.0), with 2.5–4.0 as a grey zone where free T4 by equilibrium dialysis is the next step.

The full interpretive guide is Thyroid Testing in Dogs and Cats: T4 and TSH Explained.

Cortisol: Cushing’s and Addison’s

A single resting cortisol can’t diagnose Cushing’s — cortisol is pulsatile and stress-responsive, so one random value is close to useless for hyperadrenocorticism. Diagnosis requires dynamic testing:

ACTH stimulation test: post-ACTH cortisol >22 µg/dL supports Cushing’s (17–22 µg/dL equivocal); <2 µg/dL confirms Addison’s.
Low-dose dexamethasone suppression test (LDDST): 8-hour cortisol >1.4 µg/dL = failure to suppress = Cushing’s.
Addison’s screening: a basal cortisol <2 µg/dL is highly suggestive.

The complete protocols are in Cortisol Testing in Dogs: Diagnosing Cushing’s and Addison’s Disease.

Related products: Canine T4 Test · Canine TSH Test · Feline T4 Test · Canine Cortisol Test

Sample Collection & Handling: Where Accuracy Is Won or Lost

No analyzer is more accurate than the sample you feed it. Pre-analytical errors — mistakes before the sample ever reaches the cartridge — cause more wrong results than the assay itself. Four things to control:

Serum vs. plasma vs. whole blood. Most biomarker assays are validated for serum or plasma. Check each kit insert — some accept whole blood, some don’t. Running an unvalidated sample type is a fast route to a bad number.
Anticoagulant choice. With plasma, the anticoagulant matters. Lithium or sodium heparin is generally preferred; EDTA can interfere with certain immunoassays. Confirm against the kit’s instructions.
Hemolysis, lipemia, icterus. A visibly pink (hemolyzed), milky (lipemic), or yellow (icteric) sample can skew fluorescence-based results. When the sample looks off, recollect.
Storage and timing. Acute-phase proteins and some hormones degrade over time. Separate serum or plasma promptly and respect the kit’s stability window.

The rule of thumb: if the number doesn’t match the patient, question the sample before you question the diagnosis.

How Quantitative Immunofluorescence Testing Works

All of these biomarkers share one requirement: you need a number, not a line. Qualitative tests that return “positive/negative” can’t track a trend, can’t stage CKD, and can’t distinguish a grey zone from a true positive.

Quantitative immunofluorescence analyzers — like the FIA680 and FIA880 — work by tagging antibodies with fluorescent markers and measuring the emitted signal. The fluorescence intensity is proportional to analyte concentration, so the analyzer computes an actual value in µg/dL, pmol/L, or mg/L. Results typically land in 10–20 minutes, which is what makes in-clinic biomarker panels practical.

The workflow is straightforward:

Collect serum or plasma (most biomarkers; check the specific test for whole-blood compatibility).
Load the sample into the reagent cartridge.
The analyzer runs the reaction and quantifies the result against a stored calibration curve.
Compare the value to the reference range — and, more importantly, to the patient’s previous values.

For more on the underlying technology, see What Is Fluorescence Immunochromatography (FICA)? and How to Choose a Veterinary Immunofluorescence Analyzer.

The Power of Serial Testing

A single biomarker value is a snapshot. Two or three values are a story.

That’s the single most under-used insight in biomarker medicine. Consider three patients:

A senior cat with SDMA of 12 µg/dL, then 15, then 17 six months apart. Creatinine is normal every time. The trend says early CKD — time to intervene with diet and monitoring.
A dog on antibiotics for a pyometra, CRP falling 120 → 60 → 18 mg/L. The trend confirms the treatment is working.
A hyperthyroid cat starting methimazole, T4 moving 6.2 → 4.8 → 3.1 µg/dL. The trend tells you the dose is right.

None of these decisions are possible with a qualitative yes/no. They’re only possible with numbers you can trend.

Choosing the Right Biomarker

Clinical Question	Reach For
Senior screening — kidney?	SDMA (with creatinine)
Confirm CKD staging?	SDMA + IRIS criteria
Muscle-wasted patient, kidney?	SDMA or cystatin C (not creatinine alone)
Dyspneic cat — cardiac vs respiratory?	NT-proBNP
Coughing older dog — heart or airway?	NT-proBNP
Vomiting, abdominal pain — pancreatitis?	cPL (dog) / fPL (cat)
Fever, not eating — how much inflammation?	CRP (dog) / SAA (cat)
Weight loss + ravenous appetite in a cat?	Total T4
Lethargy + weight gain in a dog?	T4 + TSH
Polyuria/polydipsia, pot-bellied dog?	Cortisol (ACTH stim / LDDST)

Application & Commercial Angle

Who should care: clinics building senior and chronic-disease panels. SDMA, NT-proBNP, CRP/SAA and related markers create billable same-visit panels and ongoing monitoring relationships.

In practice, the value is earlier staging and scheduled rechecks: each marker adds a reason to test now and again later, which is the recurring case for a quantitative analyzer.

FAQ

What’s the difference between a biomarker and a routine chemistry value?

A chemistry value (creatinine, ALT, glucose) is a direct measure of a substance already in the blood. A biomarker like SDMA or NT-proBNP is a signal — a molecule whose level changes specifically when an organ is stressed, often before the routine value moves. Biomarkers are earlier-warning systems; chemistry panels are confirmatory.

Do I need a separate sample for each biomarker?

No. One serum or plasma sample can run multiple assays. A single draw can cover SDMA, NT-proBNP, T4, and CRP — a multi-organ screen from one tube.

Are these tests accurate in both dogs and cats?

Each assay is species-specific and validated separately. Some biomarkers (SDMA) use one range for both species; others (CRP vs SAA, cPL vs fPL) are entirely different tests per species. Never run a dog assay on a cat sample.

What does “grey zone” mean?

A grey zone is the range between clearly normal and clearly abnormal — for example, 900–1800 pmol/L for canine NT-proBNP. A grey-zone result isn’t a negative and isn’t a positive; it means re-test, add another marker, or watch the trend.

How fast are results?

On a quantitative immunofluorescence analyzer, most biomarkers return in 10–20 minutes. That’s the difference between discussing a plan in the exam room versus calling the client back tomorrow.

Should biomarkers replace imaging?

No. Biomarkers localize and quantify a problem; imaging (ultrasound, echo, radiographs) characterizes it. A high NT-proBNP tells you the heart is stressed — an echocardiogram tells you why. They’re complementary.

Key Takeaways

Biomarkers detect organ dysfunction earlier than traditional chemistry — SDMA at ~25–40% kidney loss vs ~60–75% for creatinine.
Quantitative numbers enable 3 things: IRIS staging, grey-zone interpretation, and serial trend tracking that qualitative tests can’t support.
6 biomarker groups cover the organs: SDMA/cystatin C kidney, NT-proBNP cardiac, cPL/fPL pancreas, CRP/SAA inflammation, T4/TSH and cortisol endocrine.
One sample, multiple assays — a single draw screens SDMA (0–14 µg/dL), NT-proBNP, T4 and CRP together, not four separate visits.
2 serial values define the trend — progression and treatment response appear before clinical signs change.

References

IDEXX SDMA test — reference interval & clinical utility: https://www.idexx.com/en/veterinary/reference-laboratories/sdma/
International Renal Interest Society (IRIS) CKD Staging Guidelines: http://www.iris-kidney.com/guidelines/staging.html
IDEXX Cardiopet proBNP: https://www.idexx.com/en/veterinary/reference-laboratories/cardiopet-probnp/
IDEXX Spec cPL / Spec fPL: https://www.idexx.com/en/veterinary/reference-laboratories/spec-cpl-test/
Texas A&M GI Laboratory — Pancreatic Lipase Immunoreactivity: https://vetmed.tamu.edu/gilab/
Cornell eClinPath — SDMA / Adrenal / Thyroid: https://eclinpath.com/chemistry/kidney/sdma/
Ghys LFE, et al. Cystatin C: A New Renal Marker. J Vet Intern Med. 2014;28(4):1151–1164.
Cerón JJ, et al. Acute-phase proteins in dogs and cats. Vet Clin Pathol. 2005;34(2):85–99.

This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected disease should be evaluated by a veterinarian. Reference ranges are assay-dependent; always use your analyzer’s validated intervals. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.

Sources & Verification

Author: Dr. Tang — veterinary diagnostics specialist.
Review: Reference ranges and thresholds cross-checked against IDEXX, IRIS, Cornell eClinPath, and peer-reviewed veterinary literature (References above).
Last updated: 2026-08-29.
Note: Figures marked “approximate” or “assay-dependent” vary by laboratory and method; always confirm against your analyzer’s validated intervals.